| Home | E-Submission | Sitemap | Contact Us |  
top_img
J Korean Cancer Assoc > Volume 22(3); 1990 > Article
Journal of the Korean Cancer Association 1990;22(3): 451-458.
진행성 암환자에서 Interleukin - 2 와 α - Interferon 의 병합투여에 의한 Natural Killer 와 Lymphokine Activated Killer 활성의 유도
이규형
Induction of Natural Killer and Lymphokine Activated Killer Cell Activities in Patients with Advanced Cancer Treated with Combination of Interleuki
Kyoo Hyung Lee
ABSTRACT
Peripheral blood lymphucytes were obtained from 14 patients with advanced cyncer receiving combination therapy with interleukin-2 (IL-2) and a-interferon (a-IFN) as a part of a phase I study and killer cell activities were assayed against k-562 and Daudi cell lines before, during, and after the therapy. There was significant natural killer (NK) activity before the treatment (74+-77 Lytic Unit) and it increased during the treatment (day 5, 262+195 L.U., p<0.01); day 15, 431+-328 L.U., p<0.01; and day 26, 743+-506 L.U., p<0.01). Lymphokine activated killer (LAK) activity before the treatment was low (13+9 L.U.) but also increased significantly during and after the treatment (day 5,71+59 L. U., p<0.01; day 15. 63+-77 L.U.; and day 26, 290+419 L.U.). In l0 patients same assay was repeated during the second course of therapy and showed similar increase in killer cell activities without evidence of cumulative increment. Out study showed that immunotherapy with combination of IL-2 and rz-IFN induces significant levels of NK and LAK cell activities in patients with advanced cancer. This biological phenomena can be utilized as a paramenter with which the IL-2 therapy can be tailored to augment clinical efficacy and tolerability.
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Share:      
METRICS
2,357
View
14
Download
Related article
BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy  2019 October;51(4)
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI